menu
    • menu
    [{"orgOrder":0,"company":"SOLUTEX GC SL","sponsor":"OAFI Foundation (Osteoarthritis Foundation International)","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"SMP group","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"SOLUTEX GC SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOLUTEX GC SL \/ OAFI Foundation (Osteoarthritis Foundation International)","highestDevelopmentStatusID":"1","companyTruncated":"SOLUTEX GC SL \/ OAFI Foundation (Osteoarthritis Foundation International)"},{"orgOrder":0,"company":"SOLUTEX GC SL","sponsor":"SOLUTEX GC SL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SOLUTEX GC SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOLUTEX GC SL \/ SOLUTEX GC SL","highestDevelopmentStatusID":"1","companyTruncated":"SOLUTEX GC SL \/ SOLUTEX GC SL"},{"orgOrder":0,"company":"SOLUTEX GC SL","sponsor":"Robin E. Miller","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SCD-Omegatex","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SOLUTEX GC SL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SOLUTEX GC SL \/ Robin E. Miller","highestDevelopmentStatusID":"7","companyTruncated":"SOLUTEX GC SL \/ Robin E. Miller"}]

    Find Clinical Drug Pipeline Developments & Deals by SOLUTEX GC SL

    Menu

    SOLUTEX GC SL

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SOLUTEX GC SL

                            Spain arrow
                            AAPS
                            Not Confirmed

                            SOLUTEX GC SL

                            Spain arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Instituto de Investigación Sanitaria Aragón

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nutritional Intervention and Rehabilitation Treatment in Patients With Post-COVID Condition

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Post-Acute COVID-19 Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 02, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Instituto de Investigación Sanitaria Aragón

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SOLUTEX GC SL

                            Spain arrow
                            AAPS
                            Not Confirmed

                            SOLUTEX GC SL

                            Spain arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SMP group

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : OAFI Foundation (Osteoarthritis Foundation International)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Effect of Pro Resolve® Sports on Treatment of Patients With Symptomatic Knee Osteoarthrit...

                            Details : SMP group is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 01, 2022

                            Lead Product(s) : SMP group

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : OAFI Foundation (Osteoarthritis Foundation International)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SOLUTEX GC SL

                            Spain arrow
                            AAPS
                            Not Confirmed

                            SOLUTEX GC SL

                            Spain arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SCD-Omegatex

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Robin E. Miller

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Omega-3 Fatty Acids in Sickle Cell Disease

                            Details : SCD-Omegatex is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Anemia, Sickle Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2016

                            Lead Product(s) : SCD-Omegatex

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Robin E. Miller

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth